Comparative ocular and systemic pharmacokinetics of lifitegrast delivered by an eye drop and chamber- and surface-loaded contact lenses in rabbits

Treating the eye is a game of timing and volume. The surface of the eye is a delicate, self-cleaning system that constantly washes away foreign substances. When a person applies a standard eye drop, the liquid fills the small pocket under the eyelid, but the eye's natural drainage and blinking action sweep most of it away within minutes. This rapid clearance means that only a tiny fraction of the medicine ever reaches the deeper tissues where it is needed to fight inflammation or infection. For chronic conditions like dry eye disease, where the goal is to keep a steady level of medicine on the eye over many hours, this fleeting contact makes treatment difficult and inconsistent. Patients often struggle to maintain the necessary drug levels, leading to a cycle of frequent re-application that rarely solves the underlying problem of poor delivery.

Researchers have long looked for ways to hold medicine on the eye longer, and one promising avenue is the therapeutic contact lens. Unlike a standard lens that sits on the eye to correct vision, a drug-loaded lens is designed to act as a reservoir, slowly releasing medication directly onto the surface. However, while scientists have created these lenses in the lab, there has been little direct proof that they actually deliver more medicine into the eye tissues compared to a traditional drop. A new study conducted on rabbits set out to solve this uncertainty by comparing a standard eye drop against two different types of prototype contact lenses, measuring exactly how much of the drug, lifitegrast, ended up in the cornea, the conjunctiva, and other parts of the eye.

The team worked with a specific drug used to treat dry eye disease, known as lifitegrast, which works by blocking the inflammation that damages the eye's surface. They prepared three delivery methods for the rabbits: a standard eye drop, a contact lens with a hidden internal chamber that held the liquid medicine, and a contact lens with the medicine coated directly onto its surface. The researchers administered these treatments to the animals and then carefully measured the amount of drug present in the blood and various eye tissues at different times over the course of twelve hours. They also tested the safety of the solutions to ensure they would not irritate the eye.

The results showed a clear difference in how the eye handled the medicine depending on the delivery method. When the drug was given as an eye drop, it appeared in the blood and eye tissues quickly but disappeared just as fast, with levels dropping below detectable limits within two hours. In contrast, the contact lenses kept the drug in the system for much longer. The lens with the internal chamber released the medicine slowly and steadily, maintaining a consistent presence in the eye for the entire six hours the lens was worn. The lens with the surface coating released a large burst of medicine immediately, followed by a slower release, but it also kept the drug detectable for a longer period than the drop.

When the researchers calculated the total exposure of the eye tissues to the drug, the lenses proved far more effective than the drop. The lens with the internal chamber increased the amount of drug in the cornea by three times compared to the drop. The lens with the surface coating was even more dramatic, increasing the drug exposure in the cornea by 111 times. This massive increase suggests that the contact lens successfully overcame the eye's natural tendency to wash away the medicine. The study also found that the lenses kept the drug in the eye longer by slowing down the rate at which the precorneal area cleared the liquid, effectively trapping the medicine in a thin layer between the lens and the eye where it could be absorbed.

To understand exactly how this happened, the researchers built a computer model that simulated the movement of the drug from the lens into the eye tissues. This model confirmed that the lenses changed the way the eye processed the medicine. For the chamber-loaded lens, the model showed that the rate at which the drug was eliminated from the surface of the eye dropped significantly while the lens was in place. For the surface-loaded lens, the model indicated that the drug was absorbed into the cornea much faster, likely because the high concentration of medicine was held directly against the tissue. The study also looked at how these findings might translate to humans. By adjusting the model for the size of the human eye, the researchers simulated that a single daily dose from a contact lens could provide the same level of drug exposure in the human cornea as two daily doses of an eye drop.

The study did not find that the lenses were without challenges. The surface-loaded lens, while delivering the highest amount of drug, also caused a faster elimination rate from the cornea after the initial absorption, likely because the high concentration of drug pushed some of it back out toward the surface. Additionally, while the lenses increased the amount of drug in the eye, they also increased the amount of drug found in the bloodstream, raising questions about safety that would need further investigation. The researchers noted that the safety of wearing these specific lenses for long periods had not been fully tested, and the high concentrations used in the surface-loaded version were not directly tested for irritation in the same way the lower concentrations were.

Ultimately, this research provides the first direct evidence that contact lenses can significantly boost the amount of medicine that reaches the eye tissues compared to drops. The study demonstrates that by holding the drug on the surface and slowing down the eye's natural cleaning process, lenses can overcome the major limitation of current eye drop treatments. While the surface-loaded lens showed the most dramatic increase in drug delivery, the chamber-loaded lens offered a more controlled, steady release. The findings suggest that in the future, a single daily application of a drug-loaded lens could replace the need for multiple daily eye drops, offering a more consistent and effective way to treat chronic eye conditions. However, the authors caution that these results are based on animal studies and simulations, and further work is needed to confirm safety and effectiveness in people before such a treatment becomes a reality.